US Stock MarketDetailed Quotes
STTK Shattuck Labs
- 1.100
- +0.010+0.92%
Close Nov 29 13:00 ET
- 1.100
- 0.0000.00%
Post 16:48 ET
52.51MMarket Cap-718P/E (TTM)
1.140High1.100Low113.26KVolume1.100Open1.090Pre Close125.98KTurnover0.42%Turnover RatioLossP/E (Static)47.74MShares11.76052wk High0.54P/B29.97MFloat Cap0.94052wk Low--Dividend TTM27.24MShs Float60.516Historical High--Div YieldTTM3.66%Amplitude0.940Historical Low1.112Avg Price1Lot Size
Shattuck Labs Stock Forum
Sign in to post a comment
quit selling u stupid fks
1
5
$Shattuck Labs (STTK.US)$
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD...
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD...
$Shattuck Labs (STTK.US)$ Officer Schreiber Taylor purchased 14,400 shares of common stock on Jun 26, 2024 at an average price of $3.473 for a total value of $50,011.2.
$Shattuck Labs (STTK.US)$ Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
2
$Shattuck Labs (STTK.US)$ Benzinga· 2 mins ago
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
1
$Shattuck Labs (STTK.US)$
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
1
$Shattuck Labs (STTK.US)$ Shattuck Labs Announces Drug Discovery Collaboration With Ono Pharmaceutical, For Bifunctional Fusion Proteins Targeting Certain Autoimmune And Inflammatory Disease Pathways, Shattuck To Receive Upfront And Be Eligible For Milestone Payments Of Upto $227M
$Shattuck Labs (STTK.US)$ 7.50 after hours 🚀🚀🚀🚀
$Shattuck Labs (STTK.US)$ 8.00 now 🚀🚀🚀🚁
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
73358504 : It’s loading up bro. Will be back above 2.00 imo.
Johnny Mnemonic OP 73358504 : I'm still holding at $1.40
73358504 Johnny Mnemonic OP : That’s my SLO. seems like shorts want it lower but the fighting for direction has me thinking of selling right now and come back later.
73358504 : Damn it stop me out. It looks like it’ll break below 1.37 and might free fall imo.
73358504 : Hope you had a SLO bro. This POS moved as I expected.